Accenture Helping Astellas Pharma Create Next-Generation Cloud-Based IT Core Platform for Advanced Real-Time Decision Making
TOKYO; Feb. 24, 2022 – Accenture (NYSE: ACN) helped Astellas Pharma Inc. create a cloud-based core IT platform that serves as the foundation for an advanced, data-driven management model for the company’s global operations. The new platform has been rolled out in Japan, the Americas and EMEA, with plans for further deployments.
February 24, 2022
Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee Experiences
NEW YORK; Nov. 17, 2021 – Accenture (NYSE: ACN) has been selected by Organon (NYSE: OGN), a global health care company, to help establish and manage the transformation of the company’s enterprise resource planning (ERP) technology into a cloud-based digital core that will improve patient and employee experiences.
November 17, 2021
Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics
NEW YORK; Nov. 9, 2021 – Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.
November 09, 2021
Accenture Positioned as a Leader in IDC MarketScape: Worldwide Life Sciences Research & Development Vendor Assessment on IT Outsourcing for Fourth Consecutive Report
NEW YORK; Nov. 1, 2021 – For the fourth consecutive time, Accenture (NYSE: ACN) is positioned as a Leader in the IDC MarketScape vendor assessment covering IT outsourcing (ITO) across the life sciences research and development (R&D) industry.
November 01, 2021
Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report
NEW YORK; Oct. 26, 2021 – A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.
October 26, 2021
Accenture Named a Leader in the IDC MarketScape: Worldwide Life Science R&D BPO Services 2021 Vendor Assessment
NEW YORK; Sept. 30, 2021 – Accenture (NYSE: ACN) has been named a Leader in life science research and development (R&D) and business process outsourcing (BPO) services capabilities, according to a new a worldwide IDC MarketScape assessment.
September 30, 2021
Two-Thirds of Americans have had a Negative Health Care Experience, according to Accenture Research
NEW YORK; Aug. 16, 2021 – The U.S. healthcare industry could improve care experiences by engaging patients with empathy and using their trusted position to recommend appropriate digital technologies, according to a new report from Accenture (NYSE: ACN).
August 16, 2021
Digital Innovation Is Essential to Meeting Healthcare Consumers’ Expectations Post-Pandemic, According to Accenture Report
NEW YORK; June 21, 2021 – Senior healthcare executives say that moving to the cloud is among their top priorities as they reimagine how their organizations provide healthcare services to meet consumers’ evolving expectations post-pandemic, according to a new report from Accenture (NYSE: ACN).
June 21, 2021
“New Science” is Driving More Growth than Predicted Against a Changing Economic Environment, According to Accenture Report
NEW YORK; June 1, 2021 – The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research from Accenture (NYSE: ACN).
June 01, 2021
Accenture Named a Leader in Everest Group’s Veeva PEAK Services Matrix Assessment 2021
NEW YORK; May 3, 2021 – Accenture (NYSE: ACN) has been named a leader in Everest Group’s Veeva PEAK Services Matrix® Assessment 2021 report.
May 03, 2021